Skip to main content

Clinical trial BOS172738

A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)

Cancers
Organ Multiples
Trial status Trial open for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 1
Academic trial Non
Sponsor Boston pharmaceuticals
EudraCT Identifier 2018-002612-27
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03780517
Inclusion criteria Rearranged during transfection(RET) gene altered malignancy
Last update